Get your fresh news on health and wellness in New York
Provided by AGP
Proscia Wins 2026 MedTech Breakthrough Award for Turning the Moment of Diagnosis into Drug Development Insights
Honored alongside IQVIA, Medidata, and Thermo Fisher Scientific
PHILADELPHIA, May 07, 2026 (GLOBE NEWSWIRE) -- Proscia®, a company bringing pathology to the center of precision medicine, has been named a winner in the 10th annual MedTech Breakthrough Awards, marking its second consecutive year of recognition. It was honored for enabling pharmaceutical companies to advance precision therapies with real-time intelligence from routine pathology diagnoses.
“The moment of diagnosis remains one of the most underleveraged opportunities in drug development,” said Nathan Buchbinder, Chief Strategy Officer at Proscia. “Pathology data captures a rich biological signal that is often siloed and used retrospectively. This award reflects Proscia’s role in enabling pharmaceutical companies to harness these insights as drug programs demand an incredibly nuanced understanding of disease and early access to qualified candidates.”
With its Concentriq® platform, Proscia connects 16 of the top 20 pharmaceutical companies and a growing network of laboratories expected to make 8 million diagnoses annually. The platform's Proscia Aperture™ offering uses AI to analyze tissue images alongside biomarkers, molecular data, and clinical records at the moment of diagnosis, generating evidence for accelerating clinical biomarker studies, advancing companion diagnostic development, and optimizing trial matching.
“The MedTech Breakthrough Awards recognize the companies redefining what is possible in healthcare technology,” said Steve Johansson, Managing Director at MedTech Breakthrough. “Proscia stood out for tackling one of the most consequential gaps in precision medicine with both a bold vision and meaningful traction, and we are proud to recognize its leadership.”
Now celebrating its 10th anniversary, the MedTech Breakthrough Awards program has spent a decade recognizing the companies driving meaningful progress and improving patient care across the global health and medical technology industry. This year’s program drew a record-breaking number of nominations from leading companies and startups across more than 20 countries, reflecting the growing global impact and momentum of the digital healthcare industry.
About Proscia
Proscia brings enterprise-grade intelligence to pathology, powering precision medicine from drug discovery to diagnosis. Its technology is built for the pathologists, researchers, and laboratory leaders behind the most critical decisions in medicine, helping them to work fast, accurately, and at scale. Proscia is trusted by 16 of the top 20 pharmaceutical companies, and it was named Global 2026 Best in KLAS for Digital Pathology in Europe. Learn more at proscia.com, and follow Proscia on LinkedIn and X.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
Sydney Fenkell
VP, Marketing Communications
sydney@proscia.com
215.816.3436
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
